Search

Search Constraints

You searched for: Author/Creator Go, Ronald

Search Results

2. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. (29th August 2019)

3. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. (16th March 2017)

4. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. (16th March 2017)

5. Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia. Issue 3 (31st December 2019)

6. Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. (March 2018)

7. Implications and outcomes of MRD‐negative multiple myeloma patients with immunofixation positivity. Issue 3 (30th December 2019)

8. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Issue 1 (January 2021)

9. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Issue 1 (January 2021)

10. Long‐term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. Issue 3 (18th February 2014)